Flossie Wong-Staal: The Woman Who Read HIV's Genome
By 1985 the epidemic had a name and a suspect virus, but almost no one could say what the virus actually was. That year a molecular biologist at the National Cancer Institute became the first person to clone HIV and sequence it — turning an invisible killer into a legible string of genes. The map she drew made the blood test possible. For the rest of the decade she was, by citation count, the most-cited woman in science on earth.
Named for a Typhoon
She was born Wong Yee Ching on 27 August 1946 in Guangzhou, the third of four children. In 1952, with the Communist revolution consolidated on the mainland, the family fled to Hong Kong. There she attended the Maryknoll Convent School and stood out in the sciences at a moment when almost no girls in her circle were pointed toward research careers. The English name that would go on hundreds of papers was chosen by her father, who picked "Flossie" off a list of names assigned to typhoons that struck Southeast Asia — an unsentimental choice that turned out to fit.
UCLA in Three Years
She immigrated to the United States in 1964 to attend UCLA, and finished a bachelor's degree in bacteriology cum laude in three years rather than four. She stayed for a doctorate in molecular biology, awarded in 1972, and did a short postdoctoral stint at UC San Diego before leaving California. In 1971 she married Stephen P. Staal, a fellow UCLA student who became an oncologist; the couple had two daughters, Stephanie and Vega, and divorced around 1990. The hyphenated surname she kept became one of the recognisable bylines in virology.
Bethesda and the Gallo Lab
In 1973 she moved to Bethesda, Maryland, to join Robert Gallo's laboratory at the National Cancer Institute, then pursuing the then-unfashionable question of whether viruses cause human cancer. The bet paid off. Wong-Staal's work helped establish that human T-cell leukemia virus was the cause of adult T-cell leukemia — the first demonstration that a retrovirus could cause a human cancer, and the intellectual groundwork that let the same laboratory recognise what it was looking at when a second human retrovirus surfaced a decade later. Over roughly twenty years she and Gallo co-authored more than a hundred papers. "Flossie was one of the best scientists I ever worked with," Gallo said after her death.
Cloning the Virus
The AIDS work made her name. In 1985 she became the first scientist to clone HIV, and went on to produce the first genetic map of the virus — identifying its genes and their arrangement, which is the precondition for doing anything rational about a pathogen at all. The immediate payoff was diagnostic: her molecular biology underpinned the second-generation blood test, which looked for the viral genome itself rather than for the antibodies a patient's immune system had made against it, and made large-scale screening of the blood supply feasible. The longer-term payoff was therapeutic. Her group's characterisation of how much HIV varies from copy to copy — the micro-variation that lets the virus outrun any single drug — is part of the reason clinicians eventually attacked it with combinations rather than one agent at a time, the shift that turned an almost uniformly fatal infection into a manageable chronic condition.
La Jolla
In 1990 UC San Diego recruited her back to California and installed her in the Florence Riford Chair in AIDS Research, a position she held until 2002. She founded the university's Center for AIDS Research and became its chair in 1994. That same year, 1990, her team reported on the effects of the HIV-1 Tat protein on the growth of Kaposi's sarcoma cells, correlating Tat levels with the appearance of lesions. She also pushed into gene therapy, developing a protocol that used a ribozyme — an RNA "molecular knife" — to cut HIV sequences and suppress the virus in stem cells. It became only the second such protocol funded by the U.S. government. Across her career she published more than four hundred papers on retroviruses and AIDS and was named on more than four dozen HIV-related patents.
The Company Years
She retired from UCSD as professor emerita in 2002 but did not stop working. With her second husband, the neuroscientist Jeffrey McKelvy, she co-founded Immusol, serving as its chief scientific officer; in 2007 the company was renamed iTherX Pharmaceuticals and refocused on hepatitis C therapeutics. She remained a research professor of medicine at UCSD until her death on 8 July 2020, at Jacobs Medical Center in La Jolla, from complications of pneumonia. She was 73.
Why Flossie Is Called a Genius
The word has been applied to her literally: in 2007 The Daily Telegraph placed her thirty-second on a list of the "Top 100 Living Geniuses." Other bodies said it in their own vocabulary. The Institute for Scientific Information named her the top woman scientist of the 1980s, with 7,772 citations — the most-cited woman in science for that decade. The Scientist called her one of ten "superstars of science" in 1990; Discover named her one of fifty of the most extraordinary women scientists in 2002; she was elected to the U.S. Institute of Medicine and to Taiwan's Academia Sinica in 1994, and inducted into the National Women's Hall of Fame in 2019.
The specific faculty involved is molecular problem-solving executed at speed. Cloning and mapping a retrovirus nobody had characterised, and doing it fast enough that the map could be converted into a screening test while the epidemic was still expanding, is a matter of experimental design and technical judgment under conditions where a wrong guess costs a year.
The honest counter-case is that this was team science of the most intense kind. Wong-Staal's central results emerged from a large, well-funded, ferociously competitive NCI laboratory, and her hundred-plus joint papers with Gallo make individual attribution genuinely difficult in a way it is not for a lone theorist. Citation counts measure influence inside a crowded, urgent field as much as originality. And her own later programme did not close: the ribozyme gene therapy never became an approved treatment, and the company she founded pivoted away from HIV to hepatitis C. Her claim rests on the diagnostic and therapeutic consequences of her mapping work, which are enormous and concrete, rather than on a single conceptual leap.
Legacy
Every HIV blood test screening a donation, and much of the logic behind combination antiretroviral therapy, runs downstream of the genome she made readable. She also occupied a role almost no one else did in the 1980s — a Chinese-born woman leading front-rank work in American virology. "The United States is a country of immigrants," she said. "I feel very blessed to be part of it." The blessing ran both ways.
